MnRI Seminar: Histotripsy, a non-invasive robotic cancer therapy

HistoSonics is currently focused on developing the broad platform capability to non-invasively treat tumors across the body, initially focused on significant unmet needs in abdominal and liver tumors. The company is also researching and developing immuno-oncology enabling therapies, which may further benefit from the tissue lysate/effect created by histotripsy treatments, potentially offering promise to turn cold tumors hot and systemic responses to local therapy.

Dr. Stopek has more than 20 years of R&D leadership experience, including a strong background in developing image-guided technologies, new therapy platforms and combination devices to market. He currently is Vice President of R&D for HistoSonics. He formerly led R&D in various business areas at Medtronic, Covidien and US Surgical. Prior to that, he was the co-founder and VP of a startup medical device company, VMSI, working on new minimally invasive and tissue regeneration therapies. Dr. Stopek has over 200+ issued and pending patents. He received his BS, MS and PhD in Materials Science and Engineering from the University of Florida, where he also completed a fellowship in Neurosurgery and Neuroscience.

Read more about the presentation by Dr. Joshua Stopek and enter the virtual Zoom meeting.